Growth inhibition effects of isoalantolactone on K562/A02 cells: Caspase-dependent apoptotic pathways, S phase arrest, and downregulation of Bcr/Abl

Phytotherapy Research

Volumn 28, Issue 11, 2014, Pages 1679-1686

  Cai, Hong ^a,b   Meng, Xiuxiang ^a   Li, Yuzhong ^a   Yang, Chuihui ^a   Liu, Yong ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcr Abl; Isolantolactone; K562 A02; Proliferation

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; CASPASE; CYTOCHROME C; ISOALANTOLACTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG; BCR ABL PROTEIN; SESQUITERPENE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME RELEASE; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; K562 CELL LINE; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SYNTHESIS INHIBITION; S PHASE CELL CYCLE CHECKPOINT; STRUCTURE ANALYSIS; CELL CYCLE S PHASE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL;

APOPTOSIS; CASPASES; CELL PROLIFERATION; CYTOCHROMES C; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; S PHASE; SESQUITERPENES;

EID: 84915826239     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5182     Document Type: Article

References (26)

1. Bedi A, Barber JP, Bedi GC, et al. 1995. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86(3): 1148-1158.
2. Bedi A, Zehnbauer BA, Barber JP, et al. 1994. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83(8): 2038-2044.
3. Cardoso MC, Leonhardt H, Nadal-Ginard B. 1993. Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 74(6): 979-992.
4. Dirsch VM, Stuppner H, Vollmar AM. 2001. Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis. Planta Med 67(6): 557-559.
5. Felty Q, Xiong WC, Sun D, et al. 2005. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing. Biochemistry 44(18): 6900-6909.
6. Gu Y, Turck CW, Morgan DO. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366(6546): 707-710.
7. Jin YH, Choi J, Shin S, et al. 2003. Panaxadiol selectively inhibits cyclin A-associated Cdk2 activity by elevating p21WAF1/ CIP1 protein levels in mammalian cells. Carcinogenesis 24(11): 1767-1772.
8. Khan M, Ding C, Rasul A, et al. 2012. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci 8(4): 533-547.
9. King KL, Cidlowski JA. 1998. Cell cycle regulation and apoptosis. Annu Rev Physiol 60: 601-617.
10. Kluck RM, Bossy-Wetzel E, Green DR, et al. 1997. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 75(5303): 1132-1136.
11. Konishi T, Shimada Y, Nagao T, et al. 2002. Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol Pharm Bull 25(10): 1370-1372.
12. La Rosée P, Deininger MW. 2010. Resistance to imatinib: mutations and beyond. Semin Hematol 47(4): 335-343.
13. le Coutre P, Tassi E, Varella-Garcia M, et al. 2000. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95(5): 1758-1766.
14. Lozzio CB, Lozzio BB. 1975. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45(3): 321-334.
15. Morgan DO. 1995. Principles of CDK regulation. Nature 374(6518): 131-134.
16. Nimmanapalli R, Bhalla K. 2002. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 14(6): 616-620.
17. Raitano AB, Whang YE, Sawyers CL. 1997. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta 1333(3): F201-216.
18. Pal HC, Sehar I, Bhushan S, et al. 2010. Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol In Vitro 24(6): 1599-1609.
19. Sánchez-García I, Grütz G. 1995. Tumorigenic activity of the BCRABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 92(12): 5287-5291.
20. Wen J, You KR, Lee SY, et al. 2002. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277(41): 38954-38964.
21. Woo RA, Poon RY. 2003. Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2(4): 316-324.
22. Xiong Y, Hannon GJ, Zhang H, et al. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366(6456): 701-704.
23. Yadav V, Sultana S, Yadav J, et al. 2012. Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS One 7(10): e47796. doi: 10.1371/journal. pone.0047796. Epub 2012 Oct 25.
24. Yang C, Yang J, SunM, Yan J, Meng X, Ma T. 2013. Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/ Abl and P-glycoprotein expression. IUBMB Life 65(5): 435-44.
25. Zhang P, Chen JH, Dong X, et al. 2013. 6r, a novel oxadiazole analogue of ethacrynic acid, exhibits antitumor activity both in vitro and in vivo by induction of cell apoptosis and Sphase arrest. Biomed Pharmacother 67(1): 58-65.
26. Zindy F, Lamas E, Chenivesse X, et al. 1992. Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun 182(3): 1144-1154.